Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

Phase I Evaluation of Safety, Pharmacokinetics and Activity of Escalating Dose Levels of MEDI 507 in Patients Receiving Methylprednisolone for Initial Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00806208

Enrollment

Registered

2008-12-10

Start date

1999-01-31

Completion date

2000-03-31

Last updated

2008-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graft-Versus-Host Disease

Brief summary

A trial to assess safety of four doses of MEDI 507 combined with another drug for initial treatment of at least Grade II acute Graft-vs-Host Disease in recipients.

Detailed description

The primary objective of this study is to assess safety of four dose levels of MEDI 507 combined with methylprednisolone for initial treatment of at least Grade II acute GvHD in stem cell or bone marrow allograft recipients.

Interventions

DRUGMEDI-507

0.012 mg/kg MEDI 507 and Methylprednisolone

OTHERPlacebo

Placebo IV (alternative) study days 0, 3,6, and 9

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

1. allogeneic bone marrow or hematopoietic stem cell graft recipients 2. acute GvHD of at least Grade II severity 3. receipt of at least 2 mg/kg of methylprednisolone (or equivalent corticosteroid) within eight to 24 hours prior to initial receipt of study drug 4. evidence of engraftment (ANC over 1,000 cells/mm3) 5. histologic evidence of GvHD from biopsy performed during the current episode 6. receipt of GvHD prophylaxis of methotrexate, tacrolimus or cyclosporine 7. age at least 18 years 8. body weight under 130 kg 9. Both males and females are eligible, but females of childbearing potential, unless previously surgically sterilized, agree to use an effective method of birth control (e.g., abstinence, intrauterine contraceptive device, oral contraceptives, diaphragm or condom in combination with contraceptive jelly, cream or foam, Norplant7 or DepoProvera7) beginning with the first study injection and continuing through 60 days after the final study injection.

Exclusion criteria

1. previous receipt of MEDI 507 2. diagnosis of chronic GvHD 3. previous treatment with any anti-T-cell monoclonal antibodies such as OKT73 or daclizumab (Zenapax7) 4. receipt of antithymocyte globulin (ATGAM7 or other ATG) within 14 days 5. treatment with more than 0.3 mg/kg/day of methylprednisolone (or equivalent corticosteroid) for more than 72 hours for the treatment of GvHD 6. intolerance or history of intolerance to corticosteroids such that it is unlikely the patient will be able to complete at least ten days of corticosteroid therapy (2 mg/kg/day of methylprednisolone or equivalent) 7. more than one allogeneic bone marrow or hematopoietic stem cell allograft

Design outcomes

Primary

Measure	Time frame
Safety; first infusion of study drug	Through Study Day 44

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026